Suicide gene therapy in cancer: where do we stand now? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancer Letters Année : 2012

Suicide gene therapy in cancer: where do we stand now?

Résumé

Suicide gene therapy is based on the introduction into tumor cells of a viral or a bacterial gene, which allows the conversion of a non-toxic compound into a lethal drug. Although suicide gene therapy has been successfully used in a large number of in vitro and in vivo studies, its application to cancer patients has not reached the desirable clinical significance. However, recent reports on pre-clinical cancer models demonstrate the huge potential of this strategy when used in combination with new therapeutic approaches. In this review, we summarize the different suicide gene systems and gene delivery vectors addressed to cancer, with particular emphasis on recently developed systems and associated bystander effects. In addition, we review the different strategies that have been used in combination with suicide gene therapy and provide some insights into the future directions of this approach, particularly towards cancer stem cell eradication.

Dates et versions

hal-00761144 , version 1 (05-12-2012)

Identifiants

Citer

Sónia Duarte, Georges Carle, Henrique Faneca, Maria C Pedroso de Lima, Valérie Pierrefite-Carle. Suicide gene therapy in cancer: where do we stand now?. Cancer Letters, 2012, 324 (2), pp.160-70. ⟨10.1016/j.canlet.2012.05.023⟩. ⟨hal-00761144⟩
32 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More